Archives: Agenda

This forward-looking session explores how cybersecurity in financial services will evolve over the next 12–18 months. Drawing on GlobalData’s latest research, it will examine: 

• The adoption and security implications of emerging technologies – including cloud, AI, 5G, IoT, and quantum computing.
• How evolving business models and ecosystems in banking and financial services are reshaping cyber risk.
• The balance between innovation, risk, and operational resilience in an increasingly complex digital environment.

• Effective communication with target patients/families/care professionals and RETAINING them
• How inclusion of AI looks like in this communication, trust building, meeting needs and retaining engagement, from:
• Care researchers’ perspective
• Care Professionals’ perspective, and most importantly,
• Caregivers’ perspective (lived experience and real-world-evidence) in the context of “rare diseases”

• PCMs provide predictable thermal buffering
• When and why temperature control fails in pharma logistics
• Dry ice is powerful – but not trivial
• How to overcome these failures best – (where) can AI help?
• Logistics tools improving PCM benefits

Insights from the DHL logistics trend radar

• Key logistics trends impacting life sciences & healthcare
• Customer insights on adoption and priorities: LTR ECHO
• What’s next in the DHL logistics trend radar

• Moving from basic functionalities to more meaningful impact and examples of this in practice
• When AI is progressing so quickly, how will regulation evolve to match this speed?
• When is AI not the answer?
• How AI has revolutionised innovative ways of collecting data, biosimulation, and early disease diagnosis for oncology trials

Moderator: Asiyah Nawab, Senior Healthcare Analyst (Immunology Team), GlobalData

THIS SESSION WILL BE IN THE ONCOLOGY CONFERENCE ROOM

• Overview of rare diseases in Immunology
• Pharma focus on rare diseases in Immunology for drug development – where do industry interests lie?
• Challenges in rare disease trials in immunology
• Case Study – Sarepta’s Elevidys in Duchenne Muscular Dystrophy (DMD)